Remmie

Market position

Remmie operates in the connected diagnostics and telehealth device segment, positioned between consumer over-the-counter otoscopes and clinical ENT imaging equipment. Third-party data classifies it under healthcare and life sciences with verticals in medical devices, telemedicine, D2C brands and health IoT, and identifies Blueberry Pediatrics, TympaHealth and TytoCare as the closest comparable companies. It is a private company in the 1-10 to 15 employee range, with total disclosed funding reported at $4.85M by one tracker.

Remmie combines a low-cost consumer otoscope with AI-guided image capture (an "AI Eardrum Finder"), live video streaming and an asynchronous clinician-review workflow, rather than offering imaging hardware alone. Device regulatory registrations span the US, EU, Canada and Australia. A pediatric otolaryngologist quoted by the company describes the device as offering a marked improvement in image quality and resolution relative to previous over-the-counter video otoscopes. The app also accepts images from other otoscopes, and no subscription is required to use the devices themselves.

Technology

The products pair a portable otoscope camera with a cloud-enabled mobile and desktop application. Remmie 3 specifications include a 3.9 mm lens, 720p HD video up to 30 fps, an 80-degree field of view, waterproof construction, a 3000 mAh battery, 5V/1A DC power, five LED brightness levels and 2.4 GHz Wi-Fi for real-time streaming that also works without an internet connection; Remmie 4 uses a wired USB connection to phones, tablets or computers. The app provides AI-guided image capture ("AI Eardrum Finder"), live video streaming to clinicians, saved photo and video records, multiple user profiles, and HIPAA-compliant cloud storage accessible only to the account owner. Apps run on iOS/iPadOS 14 or later and Android 10 or later, with Windows and Mac versions also available. External data classifies the company's AI as application-layer.

Go-to-market

Remmie sells devices and specula through its own e-commerce storefront, supported by social channels including Facebook, Instagram, TikTok, YouTube and Twitter, and promotes FSA/HSA eligibility for purchases. A parallel professional channel targets clinicians through a physician support center covering device setup, clinical workflow integration, EMR/EHR documentation and billing and coding practices, addressing rural health communities, health clinics, hospitals and primary care and family physicians. The company has participated in accelerator and innovation programs and was named a top finalist in the Pediatric track at Pitch. Launch. in August 2025.

Consumers and families — particularly parents of young children with recurring ear infections, adults with allergies or chronic ear and sinus conditions, older adults with hearing issues, and people with mobility limitations or immune impairment — plus healthcare professionals and organizations including rural clinics, community health centers and urgent care, hospitals, primary care and family physicians, and telehealth teams.

Geography

The company is a US-based private company; third-party sources list its headquarters as Seattle, Washington and, in another listing, Culver City, California. Its devices carry regulatory registrations and clearances covering the United States (FDA Class 1 registration), Europe (CE Mark), Canada (Health Canada MDEL) and Australia (TGA), indicating availability across those markets. Products ship with free same-day shipping via the company's online store.

History

The company was founded in 2018 and has been known previously as MiVUE. It has iterated through several device generations — the Wi-Fi-connected Remmie 3, the USB-connected AI-powered Remmie 4, and the clinical-grade Remmie PRO — and has added the Remmie Report clinician-review service to its app. Third-party trackers list the company variously in Seattle, Washington and Culver City, California, and record a series of grants and accelerator participations between 2022 and 2025.

Risks & controversies

Publicly listed firmographic data is inconsistent across trackers, with headquarters given as both Seattle, Washington and Culver City, California and differing founder, funding and round records. The company's devices are FDA Class 1 registered rather than FDA cleared or approved, and Remmie explicitly states that its otoscope is an examination tool only and that it does not provide diagnosis, telehealth or prescription services, leaving clinical decisions with a user's own clinician.